SOXC Enhances NGN2 ‐Mediated Reprogramming of Glioblastoma Cells Into Neuron‐Like Cells by Modulating RhoA and RAC1 / CDC42 Pathway Activity
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.70075 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Jianjing Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Glioblastoma, rac1 GTP-Binding Protein, rhoA GTP-Binding Protein, Nerve Tissue Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Glioblastoma represents the most frequently diagnosed malignant neoplasm within the central nervous system. Human glioblastoma cells can be phenotypically reprogrammed into neuron‐like cells through the forced expression of NEUROG2 and SOXC factors. NEUROG2 serves as a pioneer factor, establishing an initial framework for this transformation. However, the specific role of SOXC factors has not been fully elucidated.
Methods
In this study, we used ChIP‐seq to determine the potential target gene of NGN2. RNA‐seq has been used to evaluate the transcriptional change during NGN2‐SOX11‐mediated neuron reprogramming. Immunofluorescence was used to determine the neuron reprogramming efficacy and cell proliferation ability. ChIP‐qPCR, Co‐IP, and Western Blot were performed to investigate the mechanism.
Results
Our findings reveal that SOXC factors, in contrast to their previously identified function as transcriptional activators, act as transcriptional repressors. They achieve this by recruiting TRIM28 to suppress the expression of ECT2, a RhoGEF. This suppression results in the differential regulation of RhoA, RAC1, and CDC42 activities throughout the reprogramming process. We further establish that small molecules targeting RhoA and its effectors can substitute for SOXC factors in facilitating the neuronal reprogramming of glioblastoma cells.
Conclusion
These results underscore the pivotal role of SOXC factors' transcriptional repression and illuminate one of their specific downstream targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Zhejiang-US Joint Laboratory for Aging and Neurological Disease Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID-Profile: Jianjing Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, J., Zhu, X., Wang, F., Chen, Z., Zhang, Y., Chen, J., Ni, H., Zhang, C. L., & Zhuge, Q. (2024). SOXC Enhances NGN2 ‐Mediated Reprogramming of Glioblastoma Cells Into Neuron‐Like Cells by Modulating RhoA and RAC1 / CDC42 Pathway Activity. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70075
Vancouver
Yang J, Zhu X, Wang F, Chen Z, Zhang Y, Chen J, et al. SOXC Enhances NGN2 ‐Mediated Reprogramming of Glioblastoma Cells Into Neuron‐Like Cells by Modulating RhoA and RAC1 / CDC42 Pathway Activity. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.70075
BibTeX
@article{Yang2024,
author = {Yang, Jianjing and Zhu, Xiaohong and Wang, Fan and Chen, Zhen and Zhang, Ying and Chen, Jiawei and Ni, Haoqi and Zhang, Chun-Li and Zhuge, Qichuan},
title = {SOXC Enhances NGN2 ‐Mediated Reprogramming of Glioblastoma Cells Into Neuron‐Like Cells by Modulating RhoA and RAC1 / CDC42 Pathway Activity},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.70075}
}
EUVIMED